Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
Ketamine One and Cognetivity will be partnering on two clinical studies under the collaboration agreement. The first study will explore ketamine-assisted therapy for depression and the second for PTSD.
Protocols for the studies have received Institutional Review Board (IRB) approval and patient recruitment is expected to occur in early 2022. Cognetivity’s Integrated Cognitive Assessment (ICA) technology will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for the conditions.
Interim CEO of Ketamine One, Adam Deffett, commented: “We’re delighted to be extending our relationship with Cognetivity through this exciting new research project.
“Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America.”
Ketamine One’s wholly-owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.
The clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool that has been deployed in clinical care, from North America and the Middle East to clinics in the UK’s National Health Service.
Ketamine One says that the project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.
CEO of Cognetivity, Dr Sina Habibi, added: “It’s great to be working with Ketamine One on these clinical studies. We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this huge market.
“These disease areas represent important use cases for the ICA beyond its core application as a device for dementia detection and diagnosis, and the fact that it can transition so smoothly into this new space confirms the strength of its fundamental capabilities and the ongoing global need for much-improved cognitive testing across a huge number of areas.”
[activecampaign form=52]
